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1. Introduction
Microbeads or microencapsulation is used to design and development of sustained release drug and enhances the  
residence  time  of  the  drug  at  the  absorption  site  using  mucoadhesive  polymers  like  sodium  alginate 1-4.  These 
mucoadhesivemicrobeads improve the bioavailability of drugs and reduce adverse effects5,  6. Microbeads are spherical in 
shape  and  small  size.  They  facilitate  the  drug  administration  procedures  and  are  stable,  cheap  and  restraint.  
Glycerinemonostearate based microbeads are useful to release the drug in a controlled manner for more than 2 hours.
Glimepiride is an oral blood sugar-lowering drug as a third generation Sulfonylurea for the management of type-II 
diabetes mellitus. It is absorbed at the gastrointestinal tract7. In type-II diabetes, insulin is not essential to manage the blood 
sugar level8. Instead, diet, and oral drugs may be sufficient. Inadequate insulin secreted by the pancreas, the elevated blood 
sugar and Glimepiride lowers the blood sugar level in the blood by stimulating insulin to be secreted from the pancreas into  
the blood8. 
The sustained release Glimepiride formulation is useful to manage the blood sugar level for the prolonged period of 
time. It is suitable to design the dosage form due to its short biological half-life of 5 hours and advantageous for diabetic  
patients. The objective of this study was to investigate the hypoglycemic effect of encapsulated Glimepiride in biological 
condition.
2. Experimental:
2.1 Materials&Methods:  Glimepiride, Glycerinemonostearate, Sodium alginateand calcium carbonate were provided by 
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2.1.1 Preparation of microbeads: Glimepiride loaded mucoadhesivemicrobeads were prepared using Sodium alginate and 
Glycerinemonostearate by orifice-ionic gelation method. Glycerinemonostearate as a mucoadhesive polymers and Sodium 
alginate were dissolved in 50 ml of the purified water to form a homogenous polymer solution. The active ingredients 150  
mg Glimepiride was added to the polymer solution and mixed well. The viscous solution was then added dropwise into the  
calcium chloride through a syringe of 22 gauge needle. The added droplets were retained in the calcium chloride solution 
and spherical microbeads were formed within a few seconds. 4000 mg, 8000 mg and 16000 mg Glycerinemonostearate and 
5%, 10% (w/v) calcium chloride were used to prepare the microbeads formulations.
Table 1: Glimepiride microbeads formulations containing Mucoadhesive polymer
Formulations GMS (mg) CaCl2 10% CaCl2 5%
F1 4000 10%
F2 8000 10%
F3 16000 10%
F4 4000 5%
F5 8000 5%
F6 16000 5%
Table 2: Microbeads formation time
Formulations Glycerinemonostearate 
(GMS) (mg)
%loading 
Efficiency
Time(seconds)
F1 4000 91 4
F2 8000 89 3
F3 16000 87 5
F4 4000 88 9
F5 8000 82 10
F6 16000 90 10
2.1.2 Estimation of Glimepiride:  IV-visible spectrophotometric method (Shimadzu) was used to determine Glimepiride 
based on the measurement of absorbance at 229 nm in phosphate buffer pH 7.8 followed by the standard validation method  
and Beer–Lambert law with the concentration of 4-20 µg/ml.
2.1.3 Efficiency of microbeads:  Adequate amount of microbeads were crushed first and weighed. This powder wasthen 
suspended in methanol to extract the drug from the microbeads so that no material was lost in the procedure. After 24 hours,  
the methanol extract solution was filtered and measured spectrophotometrically at the 229 nm for drug content against  
methanol and blank by following formula:
2.1.4 Analysis of particle size:  Prepared microbeads were filtered through the standard sieve for 10 —15 minutes on a 
mechanical shake.
2.1.5 In-Vitro Dissolution Study: USP dissolution apparatus II (VEEGO-BDA-8DR-USP Standards and Electrolab UPS-
XXII) was used to study release rate of Glimepiride microbeads with 900 ml of 0.2 M Phosphate buffer pH 7.8 at 75 rpm  
and 37 temperatures for 2 hours.At first most of the beads were floated on the dissolution medium.
A sample of the solution was withdrawn from the dissolution testing apparatus over 2 hours and the samples were 
replaced with fresh dissolution medium. The samples were diluted with 0.2 M Phosphate buffer pH 7.8 as the dilution factor 
10 times. Absorbance of these solutions was measured at 229 nm wavelength using Shimadzu Spectrophotometer.
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2.1.6 In-Vivo Test of Glimepiride Microbeads: Laboratory bred 1 month aged Long Evans Rats of either sex with 62-110 
gm body weight were employed to made the diabetes using freshly prepared solution of Aloxen (Sigma Chem, Co., St.  
Louis, USA) through gavaging at a dose of 150 mg/kg dissolved in 2 mM Citrate Buffer (pH 3.0) after an overnight fasting. 
The rats were maintained at normal photo period (12 hour dark/12 hour light) with an ambient temperature of 23-26ºC  
under adequate light and ventilation. Commercial pellet diet and water were provided to the Rats. Long Evans Rats obtained 
from the animal house, International Centre for Diarrheal Disease and Research, Bangladesh (ICDDR,B). All experimental 
studies were conducted as per the Ethical Guidelines of the National Institute of Health,  USA and proper permissions 
obtained from the relevant authorities of The University of Asia Pacific and University of Development Alternative, both at  
Dhaka, Bangladesh prior to commencing the experiments. 
After 1 week, the Rats with fasting blood glucose level of 300 mg/dL or more were considered diabetic and treated  
for this study. In this experiment a total number of 20 Rats were used. The Rats were divided into 4 groups, each group  
consisting of 5 Rats. In 4 groups of Rats each containing 2 male Rats and 3 female Rats with 62-110 gm body weight were  
used. Group 1 was kept as API of Glimepiride administration and group 2 and 3 were administered with 2 mg/kg body 
weight of mucoadhesive Glimepiride microbeads of F1, F2, F3 and F4, F5, F6 respectively. Group 4 was administered with 
commercially available dosage form of Glimepiride Tablet. 
Blood samples were collected using the retro orbital puncture method at predetermined time at 1 hour interval up to 
24 hour collected. Blood glucose levels were measured immediately by glucose oxidase method13. 
2.1.7  Kinetic  Study:  The  in-vitro  release  mechanism of  drug  from floating  tablets  were  determined  on  the  basis  of  
theoretical dissolution evaluations including zero order, first order, Higuchi kinetic model and Korsmeyer-Peppas kinetic 
model with goodness of fit test.
3. Results and Discussion:
Microbeads of Glimepiride containing glycerinemonostearate and sodium alginate were discrete, spherical and free 
flowing without coating ingredients. Microbeads were uniform with their particle size and viscosity independent. Particle  
size was not affected by the polymer of the glycerinemonostearate. The SEM photograph (Figure 1) ofmicrobeadslooked as  
spherical  and  rough  surface  with  minor  crack.  The  range  of  the  particle  size  was  from  469  to  490  52  µm  for  all 
formulations.
Six formulations were prepared using only two polymers in different quantity to test the in-vitro drug release,  
loading efficiency and the adhering ability of the microbeads to tissue in phosphate buffer pH 7.8 by the in-vitro wash-off  
test. From the study, it was found that every tested parameter were dependent on the amount of the polymer. Particle size of 
the  microbeads  was  not  affected  by the  polymer.  The  six  prepared  formulations  were  used  to  carry  out  the  in-vitro 
mucoadhesion test in phosphate buffer pH 7.8, which showed the results between the ranges from 26% to 79% within 6 
hours. The percent of mucoadhesion was higher with the lower amount of glycerinemonostearate. The previously published 
study of Prajapati  et al9 and Mankala  et al10 showed a formulation containing different polymers admixtures and coating 
ingredients but this experimental study was done using single polymer based microbeads having no coating ingredients.  
Also,bioadhesiveproperties of the microbeads were sufficient in strength with the 79% to 68% at the 1 st hour for F1 to F6 
microbeads. 
Figure 1: Scanning Electron Photomicrograph of Glimepiride Microbeads
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The  efficiency  of  microbeadswas  in  the  range  of  88%  to  91%.  Microbeadscontaining  lower  amount  of 
glycerinemonostearate  with  10%  calcium  chloride  (w/v)  showed  higher  efficiencythan  5%  calcium  chloride  (w/v). 
Efficiency of microbeadswas dependent on the amount of glycerinemonostearate and calcium chloride. The release rate of  
Glimepiride from the microbeads was varied according to the prepared formulations. The release of Glimepiride was slow 
and first in nature. The cause of such release may be for the type and amount of polymer. F1, F2, F3 microbeads containing  
glycerinemonostearate and 10% calcium chloride (w/v) showed first release and the release was completed within the 150 
minutes. The release was highest at the amount of 8000 mg of glycerinemonostearate in F2. The release of Glimepiride 
microbeads of F4, F5, F6 containing glycerinemonostearate and 5% calcium chloride (w/v)was slow but the release was  
extended over a period of 6 hours. These microbeads were suitable to prepare the Glimepiride sustained releaseformulation 
over an extended period of time without coat technique.
Table 3: Kinetic and statistical parameters obtained from drug-release data of Glimepiride microbeads formulations 
containing Mucoadhesive polymer
Formulation
Zero-order 
Model
Higuchi Kinetic 
Model Best fitted Models Release Mechanism
R2 K0 R2 Kh
F-1 0.931 0.692 0.942 7.015 Higuchi Model Diffusion & Erosion
F-2 0.923 0.783 0.953 7.13 Higuchi Model Diffusion & Erosion
F-3 0.917 0.661 0.947 6.717 Higuchi Model Diffusion & Erosion
F-4 0.892 0.510 0.971 6.164 Higuchi Model Diffusion & Erosion
F-5 0.665 0.442 0.955 5.822 Higuchi Model Diffusion & Erosion
F-6 0.914 0.239 0.940 4.094 Higuchi Model Diffusion & Erosion
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Table 4: Percentage of microbeads adhering to tissue in phosphate buffer pH 7.8
1st hour 2nd hour 3rd hour 4th hour 5th hour 6th hour
F1 79 69 58 50 47 39
F2 72 65 52 40 34 29
F3 68 60 51 42 36 30
F4 75 62 53 46 35 26
F5 73 64 57 49 38 31
F6 77 67 59 47 36 27
Glimepiride microbeads of F1, F2, F3 and F4, F5, F6 were used for In-Vivo test in Long Evans Rats. The drug  
were administered at a dose of 2 mg/kg body weight of Glimepiride solution and after oral administration a rapid reduction  
in blood glucose level was observed and maximum reduction was found at 49% within 1 hour. After 14 hour, the blood 
glucose level was recovered and 70-99 mg/dLwas considered for normal blood glucose level was considered for normal 
blood glucose level. Maximum 46% reduction was found after administration of mucoadhesive Glimepiride microbeads 
after 3 hour and sustained reduction was obtained for a long period of time. The significant reduction was considered at  
25%  blood  glucose  level.  Blood  glucose  level  was  maintained  for  10  hour  after  the  treatment  with  Glimepiride  but 
Glimepiride microbeads showed this  maintenance  for  16 to  20 houras  sustained manner.  The Glimepiride microbeads  
formulation showed a sustained hypoglycemic effect due to a slower release and absorption of drug from the microbeads 
over a  longer  period of  time.  Hence,  this  newly formulated  Glimepiride  microbeads  dosage form is  a  significant  and 
potential than immediate release glimepiride dosage form for the treatment of type-II Diabetes.
Figure 4: Comparative In-Vivo Study of Glimepiride Microbeads, and commercial dosage form.
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From the in-vitro drug release data, it was found that drugs were released for 2 to 6 hours with the highest rate of 
98%. The release data were tested with the kinetic models and found fitted with Higuchi Kinetic Model11. The release was 
non-Fickian transport and the R2 value was found 0.971. 
4. Conclusion
Sustained release Glimepiride with single polymer of glycerine monostearate could be prepared by orifice-ionic 
gelation method as it necessitates the administration of 2 to 3 doses per day. The performed in-vitro release study was  
sufficient to release the drug in a desired controlled manner from mucoadhesive Glimepiride microbeads. The results were 
showed that  the choice of combination polymers or  single polymers  will  be a potential  method for the designing and  
development of Glimepiride loaded mucoadhesive microcapsules for easy, reproducible and oral controlled drug delivery 
that is also reported by Ahad et al12.The obtained formulation was cost effective instead of using HPMC and further study 
may be suggested to improve the clinical efficiency.
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